Study of autoantibodies in Egyptian non-B,non-C chronic hepatitis patients

Bahgat, Maged; Emama, Mohamed; Refaey, Mohamed; Abd-Eldayem, Walid; Emara, Mahmoud; El-Sharkawy, Hosam; Emara, Amr; Heeba, Hayam; Akl, Mohamed Farouk

doi:10.21608/aeji.2011.8753

Cited by 1 publication

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An Egyptian study compared HCV prevalence in 2015 with a national survey made in 2008; results demonstrated ~29% reduction in HCV RNA prevalence and added that approximately 3.7 million persons are chronically infected with HCV in the age group between 15-59 years [4]. The drop in HCV prevalence between the two reports could be attributed to the national control efforts or due to significant reduction in the prevalence of human schistosomiasis, a parasitic disease whose infection is thought to be highly related to HCV infections [4,5].…”

Section: Introductionmentioning

confidence: 99%

“…It was postulated that replication and expression of HCV antigens in chronically HCV infected patients in these tissues may play a role in development of autoimmune manifestations [10]. Some autoimmune diseases were reported in Egypt like rheumatoid arthritis with prevalence of 21%, [11] autoimmune hepatitis with prevalence of 32% [5] and diabetes with prevalence of 12.6% in Egypt under age of 15 [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Seeking markers to distinguish HCV-Infected-autoimmune subjects from uninfected-autoimmune patients

Maghraby¹,

Kamel²,

Fayed³

et al. 2019

Russ Open Med J

View full text Add to dashboard Cite

Introduction -Egypt has the highest prevalence of hepatitis C virus (HCV) infection which is reported to be associated with autoimmune manifestations. Aim -There is a need for markers that enable differentiation between viral and non-infected-autoimmune patients. Material and Methods -Levels of the B-cell activation factor (BAFF), IL6, IL10 and TNF-α were quantified by ELISA in sera from HCVinfected-autoimmune patients (HCV-AI), HCV-infected patients with no autoimmune diseases (HCV-NAI), non-infected autoimmune patients (NIAI) and healthy control humans (C). Results -HCV-infected patients were 12.96, 8.33, 69.44 and 36.11% positive for the auto-antibodies ANA, AMA, ASMA and AGPCA respectively. The BAFF level was significantly (P<0.05) higher among the NI-AI patients compared to the HCV-NAI, HCV-AI patients and healthy control humans (C). For the IL6, no significant differences were seen between various patients' groups. In case of the IL10, its , levels were significantly higher (P<0.05) in the HCV-AI, NI-AI and HCV-NAI patients in comparison to the C humans. Levels of TNF-α were significantly (P<0.001 and 0.0001) higher amongst the HCV-NAI and HCV-AI than in the NI-AI patients respectively. Also, levels of the TNF-α were significantly (P<0.0001) higher amongst the C compared to the NI-AI. Levels of TNF-α were not significant amongst the HCV-NAI and HCV-AI patients than in C subjects. Conclusion -The obtained results showed that both IL6 and BAFF can serve as markers for autoimmunity and/or autoimmunity resulting from severe HCV infection, whereas, IL10 and TNF-α can be considered as markers for HCV infection in Egypt (genotype is mostly 4a).

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%